Assessment, Treatment, and Evaluation of the Patient with Elevated Triglycerides and Low HDL
1 CE Credit
Release date: August 2007
COURSE OVERVIEW:
This course will provide a scientific overview of triglycerides and HDL. Current national guidelines and the relationship between triglycerides, HDL, and cardiovascular disease will be reviewed. Special attention will be paid to the assessment of risk including information on clinical assessment, laboratory tests, and the metabolic syndrome. Many treatment options are available and will be discussed including: nutrition, exercise, weight loss, alcohol control, and medications (pharmacotherapy).

PRESENTER:
Carol M. Mason, ARNP, FAHA
USF Heart Health
University of South Florida
College of Medicine
Tampa, Florida
CE Course Outline

Step 1: Print slides/handouts (pdf)
           Clinical Reference Tool (pdf)
           Patient Handout (pdf)
Step 2: View Presentation (flash video)
Step 3: Quick Evaluation
Step 4: Print CE Certificate
PRESENTER BIO:
Ms. Mason has been involved in preventive cardiology research, lipid management and general cardiology as a nurse practitioner as well as an educator in the arena of lipid management and lipid clinic development for more than two decades. She is presently working at the University of South Florida College of Medicine as Clinical Director of the Division of Preventive Cardiology, providing direct patient care to adults living with and at risk for CVD. Ms. Mason is Vice President of the Accreditation Counsel for Clinical Lipidology, Treasurer of the Southeast Lipid Association and Past President of PCNA. She has served on the Board of Directors of PCNA since 1993. She is active in the Council of Cardiovascular Nursing as well as the Community Board of the Greater Tampa Bay American Heart Association.

COURSE EDITORS:
Cindy Conroy, RD, MA
Carol M. Mason, ARNP, FAHA
Jane Nelson Worel, RN, MS
Terry Thomas, RN, MSN
Tell A Friend...
about this continuing education opportunity! Simply enter the email address of up to 3 colleagues, friends or family members and we will email them information about this program.

Email Addresses:
My Name:
My Email:

EDUCATIONAL OBJECTIVES:
Upon completion of this program, participants will be able to:
  1. Review guidelines and goals of therapy for managing patients with elevated triglycerides and/or low HDL-cholesterol.
  2. Site the three first line pharmacologic agents used in the treatment of very high triglycerides.
  3. Identify three nutrition-related lifestyle changes to reduce triglycerides and increase HDL.
  4. Identify common non-pharmacologic and pharmacologic causes of elevated triglycerides.
AUDIENCE:
The audience for this course consists of nurses and nurse practitioners specializing in cardiovascular disease prevention and management.

PRESENTER DISCLOSURES:
Speaker's Bureau: AstraZeneca, Pfizer, Merck/Schering-Plough, Reliant Consultant: AstraZeneca, Pfizer, Merck/Schering-Plough, Merck, Reliant

SPONSOR/ACCREDITOR:
This activity is sponsored by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners (AANP) - provider number 030602. PCNA will provide 1 contact hour of continuing education for this program.

GRANTOR:
This continuing education activity is supported by an unrestricted educational grant from Abbott Laboratories.

COST:
This online educational activity is offered free of charge.

PARTICIPATION IN THE ACTIVITY AND RECEIPT OF CERTIFICATE OF CREDIT:
Complete the online course and short evaluation to access a printable certificate of completion.

REFERENCES:
  • JAMA, May 16, 2001-Vol. 285, No. 19, 2493.
  • AHA. www.americanheart.org/presenter.jhtml?identifier=4778
  • Assmann, et al. Eur Heart J. 1998; 19(suppl A): A2.
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001; 285:2486.
  • Stone, N., Blum, C. Management of Lipids in Clinical Practice, Professional Communications, Inc., 2005.
  • Diabetes Care 28: 2577-1584, 2005.
  • JAMA,185: 1486-2497
  • Gotto, A., Pownall, H. Manual of Lipid Disorders, Williams & Wilkins, 1999.
  • Kannel WB. Am J Cardiol. 1983; 52:9B-12B.
  • Mosca, L. Circulation 2004; 109; 672-693.
  • Rubins HB, et al. N Engl J Med. 1999; 341:410-418.
  • Adapted with permission from the American Diabetes Association from Diabetes Care. 2004:27(suppl 1): S68-S71.
  • Ballantyne, CM., O'Keefe, JH., Gotto, AM. Dyslipidemia Essentials, 2005.
  • NHLBI, ATP lll.
  • Fletcher, et al, Managing Abnormal Blood Lipids, Circulation, Nov. 15, 2005.
  • Blair, S., et al, Active Living Every Day. Human Kinetics, March 2001.
  • Tudor-Locke, C., Bassett, D., How Many Steps/Day are Enough? Preliminary Pedometer Indices for Public Health, Sports Medicine, 34(1), 2004.
  • Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. www.FDA.gov/cder/ob/default.htm.
  • Kris-Etherton, P., Arterioscler Thromb Vasc Biol. 2003; 23151-152.
  • NCEP/ATP III, May 2001.
  • Cardiovascular Nutrition Strategies & Tools for Disease Management & Prevention, ADA, 1998.